OCSAW
HEALTHCAREOculis Holding AG - Warrants (02/03/2028)
$18.39+0.94 (+5.36%)LIVE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving OCSAW Today?
No stock-specific AI insight has been generated for OCSAW yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$4.85$19.72
$18.39
Fundamentals
Market Cap—
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume6K
Avg Volume (10D)—
Shares Outstanding—
OCSAW News
21 articles- Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational TrialYahoo Finance·May 7, 2026
- Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual MeetingGlobeNewswire Inc.·May 5, 2026
- Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual MeetingYahoo Finance·May 1, 2026
- Should Oculis Completing Phase 3 Trials for Topical DME Drug OCS-01 Require Action From OCS Investors?Yahoo Finance·Apr 29, 2026
- Oculis Publishes Invitation to the Annual General MeetingYahoo Finance·Apr 21, 2026
- Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular EdemaYahoo Finance·Apr 20, 2026
- Oculis to Participate in Upcoming Investor ConferencesGlobeNewswire Inc.·Apr 7, 2026
- Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic NeuritisGlobeNewswire Inc.·Mar 31, 2026
- Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic NeuritisGlobeNewswire Inc.·Mar 31, 2026
- Oculis Holding AG (OCS) Reports Q3 Loss, Beats Revenue EstimatesYahoo Finance·Nov 10, 2025
- Oculis Reports Q3 2025 Financial Results and Provides Company UpdateYahoo Finance·Nov 10, 2025
- Oculis to Participate in Upcoming November Investor ConferencesYahoo Finance·Nov 5, 2025
- Why Oculis Holding (OCS) Is Raising $110 Million to Advance Privosegtor and What That Means for InvestorsYahoo Finance·Nov 2, 2025
- Oculis Holding (OCS): Is the Premium Price-to-Book Ratio Justified After Recent Share Price Gains?Yahoo Finance·Nov 2, 2025
- Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor DevelopmentYahoo Finance·Oct 30, 2025
- Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025Yahoo Finance·Oct 14, 2025
- Oculis Holding AG (OCS) Soars 6.3%: Is Further Upside Left in the Stock?Yahoo Finance·Oct 10, 2025
- Oculis Holding (NasdaqGM:OCS) Valuation Spotlight as Privosegtor Advances Toward Pivotal Neuroprotection TrialsYahoo Finance·Oct 9, 2025
- Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective TherapyYahoo Finance·Oct 6, 2025
- Strength Seen in Oculis Holding AG (OCS): Can Its 6.7% Jump Turn into More Strength?Yahoo Finance·Sep 23, 2025
- Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMSYahoo Finance·Sep 22, 2025
All 21 articles loaded
Price Data
Open$0.00
Previous Close$17.45
Day High$0.00
Day Low$0.00
52 Week High$19.72
52 Week Low$4.85
52-Week Range
$4.85$19.72
$18.39
Fundamentals
Market Cap—
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume6K
Avg Volume (10D)—
Shares Outstanding—
About Oculis Holding AG - Warrants (02/03/2028)
Oculis Holding AG, a biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company is headquartered in Zug, Switzerland.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—